Bone News and Research

RSS

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

Amedica, Orthopaedic Synergy sign SiN articulating hip and knee implant Joint Venture Development Agreement

Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.

22 Feb 2010

Cord Blood America announces aim to be world's largest stem cell storage facility

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, for families nationwide and internationally, said today in an interview of Matthew Schissler, co-founder and CEO, by analyst Francis Gaskins, that its goal is to be the world's largest stem cell storage facility.

22 Feb 2010

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

The United States government's decision last year to lift restrictions on federally-funded stem cell research has helped the nation's stem-cell researchers concentrate on science, but limitations remain - even under the new policy, according to George Daley, a Howard Hughes Medical Institute investigator at Children's Hospital Boston.

22 Feb 2010

Scientists develop new mathematical model to understand CML better

Doctors can now understand better chronic myeloid leukaemia (CML), including how it responds to therapy, thanks to a new mathematical model for the disease, developed by scientists in Portugal, Belgium and the United States. The work, to be published in the June edition of the journal Haematologica, also reveals that current therapies - which are not believed to cure CML - with the right protocol can actually get rid of the disease, and provides guidelines on how to do that.

21 Feb 2010

OrthoAccel Technologies promotes AcceleDent System for enhancing orthodontics at 7th IOC

OrthoAccel Technologies, Inc., developers of the AcceleDent System, which is an acceleration device to enhance orthodontics, recently exhibited at the 7th International Orthodontic Congress (IOC) in Sydney, Australia, which is held by the World Federation of Orthodontists (WFO) every five years. The 8th IOC in 2015 will be hosted in London.

20 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Genoptix, Inc., a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it.

19 Feb 2010

Most important osteoporosis meeting of 2010: More than 850 abstracts received

More than 850 abstracts have been received - guaranteeing broad global attendance at the year's most noteworthy platform for osteoporosis research. Don't miss the most important osteoporosis meeting of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

19 Feb 2010

U.S. Patent and Trademark office issues Patent on Positron’s Tech-Assist

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the U.S. Patent and Trademark office has allowed for issuance a Patent on Positron’s Tech-Assist™. The Tech-Assist™, invented under the direction of John A. Zehner, a nuclear pharmacist, dramatically reduces exposure to the worker while injecting radiopharmaceuticals into patients when performing Positron Emission Tomography (PET) imaging studies.

19 Feb 2010

Six states to study sickle cell disease and thalassemias in national pilot project

Medical researchers are developing a new surveillance system to determine the number of patients diagnosed with a family of inherited blood disorders known as hemoglobinopathies, including sickle cell disease, thalassemias, and hemoglobin E disease.

19 Feb 2010

Researchers find gene mutations that may provide clues for treating AML patients

Although leukemia is one of the best studied cancers, the cause of some types is still poorly understood. Now, a newly found mutation in acute myeloid leukemia patients could account for half of the remaining cases of adult acute leukemia with an unknown origin.

19 Feb 2010

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

Since the brain-injuring virus needs mosquitoes and pigs to spread, government officials should ban standing water in cemetery cisterns and urban drainage ditches. They should keep industrial "piggeries" away from cities and their populations.

19 Feb 2010

FDA approves Rituxan-FC combination therapy for CLL

Genentech, Inc., a wholly owned member of the Roche Group, and Biogen Idec announced today the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab) in combination with fludarabine and cyclophosphamide (FC) for people with previously untreated and previously treated CD20-positive chronic lymphocytic leukemia (CLL).

18 Feb 2010

Rituxan, intended for patients with CLL receives FDA approval

The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.

18 Feb 2010

Fourth-quarter and fiscal year 2009 results announced by DJO Incorporated

DJO Incorporated, a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC (“DJOFL”), for the fourth quarter and fiscal year ended December 31, 2009. ReAble Therapeutics, Inc. (“ReAble”) acquired DJO Incorporated (“DJO Opco”) in a transaction completed on November 20, 2007 (the “DJO Merger”).

18 Feb 2010

Vertebroplasty effective in treatment of VCFs

The results of a study of more than 4500 patients from six Italian EVEREST (European Vertebroplasty Research Team) Centers (Dr. G.C. Anselmetti-Candiolo Torino, Dr. G. Bonaldi-Bergamo, Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma, Dr. M. Muto-Napoli,) confirms the effectiveness of vertebroplasty in treating vertebral compression fractures (VCFs), finding that the procedure provides significant and sustained pain relief.

18 Feb 2010

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Gilead Sciences, Inc. announced Phase II clinical trial results today showing that its investigational fixed-dose single-tablet “Quad” regimen of elvitegravir, GS 9350 (cobicistat) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection exhibited antiretroviral activity comparable to that of Atripla® (efavirenz 600 mg/ emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

18 Feb 2010

Bone News and Research

Study shows CEL-2000 vaccine blocks RA progression in mice

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

Amedica, Orthopaedic Synergy sign SiN articulating hip and knee implant Joint Venture Development Agreement

Cord Blood America announces aim to be world's largest stem cell storage facility

U.S. government's decision helped stem-cell researchers concentrate on science, but limitations remain

Scientists develop new mathematical model to understand CML better

OrthoAccel Technologies promotes AcceleDent System for enhancing orthodontics at 7th IOC

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Most important osteoporosis meeting of 2010: More than 850 abstracts received

U.S. Patent and Trademark office issues Patent on Positron’s Tech-Assist

Six states to study sickle cell disease and thalassemias in national pilot project

Researchers find gene mutations that may provide clues for treating AML patients

Walker's book focuses on deaths, genetic deformities and other health issues resulting from environmental pollution

FDA approves Rituxan-FC combination therapy for CLL

Rituxan, intended for patients with CLL receives FDA approval

Fourth-quarter and fiscal year 2009 results announced by DJO Incorporated

Vertebroplasty effective in treatment of VCFs

Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News